{
    "clinical_study": {
        "@rank": "21537", 
        "acronym": "PRC-05-2011", 
        "arm_group": [
            {
                "arm_group_label": "Intensive Care (IC)", 
                "arm_group_type": "Active Comparator", 
                "description": "Rheumatologists treating to target of DAS28<2.6"
            }, 
            {
                "arm_group_label": "Routine Care (RC)", 
                "arm_group_type": "No Intervention", 
                "description": "Participants treated in the routine manner by their rheumatologist (not treated to the target of DAS28<2.6)"
            }
        ], 
        "brief_summary": {
            "textblock": "Canadian Rheumatologists will be randomized to treat their participants with active\n      Psoriatic Arthritis to a target (disease activity score <2.6), or as per their routine care.\n      The aim of this study is to determine whether treating to a target results in greater\n      disease improvement than treating patients using routine care."
        }, 
        "brief_title": "Psoriatic Arthritis Treat to Target vs. Usual Care", 
        "condition": "Psoriatic Arthritis (PsA)", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Psoriatic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Psoriatic Arthritis as diagnosed by a rheumatologist and meeting ACR classification\n             criteria for PsA or CASPAR criteria\n\n          -  The subject must provide written informed consent for participation in the study\n             before any study specific procedures are performed\n\n          -  Subject has 3 or more SJC on 28 joint count\n\n          -  Age >=18\n\n        Exclusion Criteria:\n\n          -  Subject has a history of being non-compliant\n\n          -  Serious concomitant illnesses that in the investigator's opinion negate ability to\n             optimally treat the patient\n\n          -  If treating with TNF inhibitor, positive PPD > 5mm who have not received INH for\n             recommended course or untreated TB (ie CXR evidence of latent infection). Usual\n             screening is in place for standard of care.\n\n          -  Pregnancy, breast-feeding or considering pregnancy over the next 12 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "230", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692912", 
            "org_study_id": "PRC-05-2011"
        }, 
        "intervention": {
            "arm_group_label": "Intensive Care (IC)", 
            "description": "Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28<2.6", 
            "intervention_name": "Intensive Care", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Psoriatic Arthritis", 
            "Randomized", 
            "Single blind", 
            "Treat to target"
        ], 
        "lastchanged_date": "November 13, 2013", 
        "location": [
            {
                "contact": {
                    "email": "Janet.Pope@sjhc.london.on.ca", 
                    "last_name": "Janet E. Pope, MD, MPH, FRCPC", 
                    "phone": "1-519-619-7317"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6G 2S3"
                    }, 
                    "name": "Pope Research Corp., 68 Green Acres Drive"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newmarket", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "The Arthritis Program Research Group"
                }, 
                "investigator": {
                    "last_name": "Carter Thorne, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M9C 5N2"
                    }, 
                    "name": "Arthur Karasik"
                }, 
                "investigator": {
                    "last_name": "Arthur Karasik, MD, FRCPC", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2L 1S6"
                    }, 
                    "name": "Institut de Rheumatologie de Montreal"
                }, 
                "investigator": {
                    "last_name": "Boulos Haraoui, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial of Active Psoriatic Arthritis (PsA): Randomizing to Treat to a Target vs. Usual Care", 
        "overall_contact": {
            "email": "Janet.Pope@sjhc.london.on.ca", 
            "last_name": "Janet E. Pope, MD, MPH, FRCPC", 
            "phone": "1-519-619-7317"
        }, 
        "overall_official": {
            "affiliation": "Pope Research Corp., University of Western Ontario, St. Joseph's Health Care London", 
            "last_name": "Janet E. Pope, MD, MPH, FRCPC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure will be the percentage of patients achieving low Disease Activity Score (DAS<2.6) in each patient group (Intensive Care vs. Routine Care) at the end of the study.", 
            "measure": "Percentage of patients achieving low DAS", 
            "safety_issue": "No", 
            "time_frame": "Month 9 Visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692912"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Compares the effectiveness of Intensive Care and Routine Care groups, as measured by the time to achieving target of DAS28<2.6", 
                "measure": "Time to achieving DAS28<2.6", 
                "safety_issue": "No", 
                "time_frame": "Month 3 Visit, Month 6 Visit, and Month 9 Visit"
            }, 
            {
                "description": "To compare the effectiveness of Intensive Care and Routine Care in improving the patient DAS28.", 
                "measure": "Absolute change in DAS28", 
                "safety_issue": "No", 
                "time_frame": "Month 3 Visit, Month 6 Visit, Month 9 Visit"
            }, 
            {
                "description": "ACR 20/50/70 defined as:\n20%, 50%, or 70% reduction in tender joint count, and\n20%, 50%, or 70% reduction in swollen joint count, and\na 20%, 50%, or 70% reduction in 3 of the following 5 measures:\nPatient and physician global assessments (VAS)\nPatient pain score (VAS)\nHAQ-DI\nESR or CRP", 
                "measure": "Percentage of Patients achieving ACR 20, 50, and 70", 
                "safety_issue": "No", 
                "time_frame": "Month 3 Visit, Month 6 Visit, Month 9 Visit"
            }, 
            {
                "description": "PsARC defined as improvement in at least 2 of the 4 following measures, one of which must be joint swelling or tenderness, and no worsening in any of the 4 measures:\nMDGA (0-5 point scale): reduction by 1 point.\nPGA (0-5 point scale): reduction by 1 point.\nTJC (76 or 68): reduction by >=30%.\nSJC (76 or 68): reduction by >=30%.", 
                "measure": "Percentage of patients achieving PsARC", 
                "safety_issue": "No", 
                "time_frame": "Month 3 Visit, Month 6 Visit, Month 9 Visit"
            }, 
            {
                "description": "HAQ-DI is a self-administered questionnaire using the patient's functional ability during the last week. It consists of 20 items converging to 8 scales measuring dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. The patients rate each activity as 0 = without any difficulty, 1 = some difficulty, 2 = much difficulty and 4 = unable. The final score ranges from 0 to 3 with higher scores indicating more disability.", 
                "measure": "Absolute change in HAQ-DI", 
                "safety_issue": "No", 
                "time_frame": "Month 3 Visit, Month 6 Visit, Month 9 Visit"
            }
        ], 
        "source": "Pope Research Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pope Research Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}